

Edwards Lifesciences Corp
Form 10-Q
July 28, 2017
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the Quarterly Period Ended June 30, 2017

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the transition period from _____ to _____
Commission file number 1-15525

EDWARDS LIFESCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 36-4316614

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

One Edwards Way, Irvine, California 92614
(Address of principal executive offices) (Zip Code)

(949) 250-2500
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

		Non-accelerated filer <input type="checkbox"/>		
Large accelerated filer <input checked="" type="checkbox"/>	Accelerated filer <input type="checkbox"/>	(Do not check if a smaller reporting company)	Smaller reporting company <input type="checkbox"/>	Emerging growth company <input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Edgar Filing: Edwards Lifesciences Corp - Form 10-Q

The number of shares outstanding of the registrant's common stock, \$1.00 par value, as of July 24, 2017 was 211,158,030.

Table of Contents

EDWARDS LIFESCIENCES CORPORATION
FORM 10-Q
For the quarterly period ended June 30, 2017

TABLE OF CONTENTS

	Page Number
<u>Part I. FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements (Unaudited)</u>	<u>1</u>
<u>Consolidated Condensed Balance Sheets</u>	<u>1</u>
<u>Consolidated Condensed Statements of Operations</u>	<u>2</u>
<u>Consolidated Condensed Statements of Comprehensive Income</u>	<u>3</u>
<u>Consolidated Condensed Statements of Cash Flows</u>	<u>4</u>
<u>Notes to Consolidated Condensed Financial Statements</u>	<u>5</u>
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>21</u>
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	<u>29</u>
<u>Item 4. Controls and Procedures</u>	<u>30</u>
<u>Part II. OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	<u>31</u>
<u>Item 1A. Risk Factors</u>	<u>31</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>31</u>
<u>Item 5. Other Information</u>	<u>31</u>
<u>Item 6. Exhibits</u>	<u>31</u>
<u>Signature</u>	<u>32</u>
<u>Exhibits</u>	<u>33</u>

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in millions, except par value; unaudited)

	June 30, 2017	December 31, 2016
ASSETS		
Current assets		
Cash and cash equivalents	\$508.2	\$ 930.1
Short-term investments (Note 5)	623.6	341.0
Accounts and other receivables, net of allowances of \$8.5 and \$9.0, respectively	510.7	414.6
Inventories (Note 2)	491.6	396.6
Prepaid expenses	54.1	45.9
Other current assets	95.2	111.8
Total current assets	2,283.4	2,240.0
Long-term investments (Note 5)	551.5	532.1
Property, plant, and equipment, net	627.9	580.0
Goodwill (Note 4)	965.1	626.1
Other intangible assets, net (Note 4)	408.6	204.8
Deferred income taxes	185.2	203.8
Other assets	116.8	123.2
Total assets	\$5,138.5	\$ 4,510.0
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (Note 2)	\$562.5	\$ 532.5
Long-term debt	1,016.8	822.3
Contingent consideration liabilities (Notes 4 and 6)	198.7	31.6
Other long-term liabilities	420.9	504.6
Commitments and contingencies (Note 9)		
Stockholders' equity		
Preferred stock, \$.01 par value, authorized 50.0 shares, no shares outstanding	—	—
Common stock, \$1.00 par value, 350.0 shares authorized, 244.7 and 242.6 shares issued, and 211.1 and 211.6 shares outstanding, respectively	244.7	242.6
Additional paid-in capital	1,267.0	1,167.8
Retained earnings	4,331.9	3,906.3
Accumulated other comprehensive loss	(157.8)	(198.4)
Treasury stock, at cost, 33.6 and 31.0 shares, respectively	(2,746.2)	(2,499.3)
Total stockholders' equity	2,939.6	2,619.0
Total liabilities and stockholders' equity	\$5,138.5	\$ 4,510.0

The accompanying notes are an integral part of these consolidated condensed financial statements.

Table of ContentsEDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(in millions, except per share information; unaudited)

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2017	2016	2017	2016
Net sales	\$841.8	\$759.3	\$1,725.3	\$1,456.6
Cost of sales	211.1	202.5	426.7	382.8
Gross profit	630.7	556.8	1,298.6	1,073.8
Selling, general, and administrative expenses	243.8	228.8	473.4	441.5
Research and development expenses	134.4	112.5	263.1	214.3
Intellectual property litigation expenses	7.7	9.1	17.9	21.3
Change in fair value of contingent consideration liabilities (Note 4)	3.1	0.4	4.2	1.0
Special charges (Note 3)	31.2	34.5	31.2	34.5
Interest expense, net	1.4	2.4	3.8	4.8
Other expenses, net	3.5	0.1	5.8	4.1
Income before provision for income taxes	205.6	169.0	499.2	352.3
Provision for income taxes	19.5	42.4	82.9	82.7
Net income	\$186.1	\$126.6	\$416.3	\$269.6
Share information (Note 11)				
Earnings per share:				
Basic	\$0.88	\$0.60	\$1.97	\$1.27
Diluted	\$0.86	\$0.58	\$1.93	\$1.24
Weighted-average number of common shares outstanding:				
Basic	210.5	212.2	210.8	212.6
Diluted	215.7	217.3	216.1	217.6

The accompanying notes are an integral part of these consolidated condensed financial statements.

Table of Contents

EDWARDS LIFESCIENCES CORPORATION
 CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
 (in millions; unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2017	2016	2017	2016
Net income	\$186.1	\$126.6	\$416.3	\$269.6
Other comprehensive income (loss), net of tax (Note 10):				
Foreign currency translation adjustments	37.2	(6.7)	60.9	20.9
Unrealized loss on cash flow hedges	(12.3)	(1.2)	(18.6)	(20.8)
Defined benefit pension plans	0.1	—	0.1	—
Unrealized (loss) gain on available-for-sale investments	(1.6)	1.5	(2.6)	3.2
Reclassification of net realized investment loss to earnings	0.3	0.3	0.8	0.6
Other comprehensive income (loss)	23.7	(6.1)	40.6	3.9
Comprehensive income	\$209.8	\$120.5	\$456.9	\$273.5

The accompanying notes are an integral part of these consolidated condensed financial statements.

Table of Contents

EDWARDS LIFESCIENCES CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in millions; unaudited)

	Six Months Ended June 30,	
	2017	2016
Cash flows from operating activities		
Net income	\$416.3	\$269.6
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	40.0	33.9
Stock-based compensation (Note 8)	30.5	28.6
Excess tax benefit from stock plans (Note 1)	—	(37.2)
Impairment and other charges (Note 3)	31.0	—
Gain on investments, net	(3.7)	(1.0)
Deferred income taxes	43.7	0.2
Purchased in-process research and development	5.7	34.5
Other	6.9	3.8
Changes in operating assets and liabilities:		
Accounts and other receivables, net	(70.5)	(64.7)
Inventories	(72.2)	(14.7)
Accounts payable and accrued liabilities	(63.8)	(12.9)
Income taxes	(46.0)	60.9
Prepaid expenses and other current assets	1.3	(14.0)
Other	6.8	10.4
Net cash provided by operating activities	326.0	297.4
Cash flows from investing activities		
Capital expenditures	(73.9)	(64.8)
Purchases of held-to-maturity investments (Note 5)	(505.6)	(454.5)
Proceeds from held-to-maturity investments (Note 5)	232.0	347.3
Purchases of available-for sale investments (Note 5)	(332.3)	(174.8)
Proceeds from available-for-sale investments (Note 5)	289.4	94.8
Investments in intangible assets and in-process research and development	(6.4)	(41.1)
Investments in trading securities, net	(5.8)	(5.2)
Investments in unconsolidated affiliates, net (Note 5)	0.3	(2.0)
Acquisition of business, net of cash acquired (Note 4)	(84.8)	—
Other	0.1	4.5
Net cash used in investing activities	(487.0)	(295.8)
Cash flows from financing activities		
Proceeds from issuance of debt	985.4	15.9
Payments on debt and capital lease obligations	(808.2)	(19.3)
Purchases of treasury stock	(511.2)	(380.7)
Equity forward contract related to accelerated share repurchase agreement	—	(35.0)
Excess tax benefit from stock plans (Note 1)	—	37.2
Proceeds from stock plans	68.7	44.6
Other	0.8	(0.1)
Net cash used in financing activities	(264.5)	(337.4)
Effect of currency exchange rate changes on cash and cash equivalents	3.6	(12.7)
Net decrease in cash and cash equivalents	(421.9)	(348.5)

Edgar Filing: Edwards Lifesciences Corp - Form 10-Q

Cash and cash equivalents at beginning of period	930.1	718.4
Cash and cash equivalents at end of period	\$508.2	\$369.9
Supplemental disclosures:		
Non-cash investing and financing transactions:		
Fair value of shares issued in connection with business combinations (Note 4)	\$266.5	\$—
Capital expenditures accruals	\$16.2	\$17.2

The accompanying notes are an integral part of these consolidated condensed financial statements.

Table of Contents

1. BASIS OF PRESENTATION

The accompanying interim consolidated condensed financial statements and related disclosures have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") and should be read in conjunction with the consolidated financial statements and notes included in Edwards Lifesciences Corporation's Annual Report on Form 10-K for the year ended December 31, 2016. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles ("GAAP") have been condensed or omitted.

In the opinion of management of Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company"), the interim consolidated condensed financial statements reflect all adjustments considered necessary for a fair statement of the interim periods. All such adjustments are of a normal, recurring nature. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.

Recently Adopted Accounting Standards

In March 2016, the Financial Accounting Standards Board ("FASB") issued an amendment to the guidance on stock compensation. The amendment simplifies several aspects of the accounting for share-based payment award transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance was effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company adopted this standard effective January 1, 2017. The impact of the standard was as follows:

- the Company recorded excess tax benefits of \$39.5 million as a benefit to the "Provision for Income Taxes" for the six months ended June 30, 2017. Previously, this amount would have been recorded to "Additional Paid-in Capital";

- the new standard eliminates the requirement that excess tax benefits be realized through a reduction in income taxes payable before a company can recognize them. As a result, on January 1, 2017, the Company recorded, on a modified-retrospective basis, a cumulative-effect adjustment of \$9.3 million in retained earnings for excess tax benefits not previously recognized;

- in the diluted earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. This did not have a material impact on the Company's diluted net earnings per share calculation;

- the new standard requires that excess tax benefits be reported as operating activities in the consolidated statements of cash flows. Previously, these cash flows were included in financing activities. The Company elected to apply this change on a prospective basis;

- the new standard requires that employee taxes paid when an employer withholds shares for tax-withholding purposes be reported as financing activities in the consolidated statements of cash flows. This had no impact since the Company has historically presented these amounts as a financing activity; and

- the Company elected not to change its policy on accounting for forfeitures, and continued to estimate forfeitures expected to occur to determine the amount of compensation cost to be recognized each period.

New Accounting Standards Not Yet Adopted

In March 2017, the FASB issued an amendment on the guidance on retirement benefits. The amendment requires that an employer disaggregate the service cost component from the other components of net benefit cost. The amendment also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the income statement and allows only the service cost component of net benefit cost to be eligible for capitalization. The guidance is effective for periods beginning after December 15, 2017, including interim periods within those annual periods. The guidance related to the presentation of the service cost component and the other components of net benefit cost in the income statement must be applied retrospectively, and the guidance related to the capitalization of the service cost component of net benefit cost must be applied prospectively. The Company does not expect the adoption of this guidance will have a material impact on its consolidated financial statements.

Table of Contents

2. COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS

Components of selected captions in the consolidated condensed balance sheets consisted of the following (in millions):

	June 30, 2017	December 31, 2016
Inventories		
Raw materials	\$79.2	\$ 60.6
Work in process	122.4	102.4
Finished products	290.0	233.6
	\$491.6	\$ 396.6

At June 30, 2017 and December 31, 2016, \$79.4 million and \$64.2 million, respectively, of the Company's finished products inventories were held on consignment.

	June 30, 2017	December 31, 2016
Accounts payable and accrued liabilities		
Accounts payable	\$104.6	\$ 97.1
Employee compensation and withholdings	162.6	216.1
Property, payroll, and other taxes	35.8	35.3
Research and development accruals	37.3	40.0
Accrued rebates	39.6	36.1
Fair value of derivatives	15.4	3.3
Accrued marketing expenses	12.7	12.6
Taxes payable (Note 12)	65.4	5.9
Litigation reserves	8.3	7.8
Other accrued liabilities	80.8	78.3
	\$562.5	\$ 532.5

3. SPECIAL CHARGES

Impairment of Long-lived Assets

In June 2017, the Company recorded a \$31.2 million charge related to the other-than-temporary impairment of one of its cost method investments and an associated long-term asset related to the Company's option to acquire this investee. The Company concluded that the impairment of these assets was other-than-temporary based upon recent review of the investee's clinical data and trial results, which did not support continuation of the product development effort, and the financial condition and near term prospects of the investee.

Acquisition of In-process Research and Development ("IPR&D")

In May 2016, the Company entered into two separate agreements to acquire technologies for use in its transcatheter heart valve programs. In connection with these agreements, the Company recorded an IPR&D charge totaling \$34.5 million. The acquired technologies are in the early stages of development and have no alternative uses. Additional design developments, bench testing, pre-clinical studies, and human clinical studies must be successfully completed prior to selling any product using these technologies.

Table of Contents

4. ACQUISITION

On November 26, 2016, the Company entered into an agreement and plan of merger to acquire Valtech Cardio Ltd. ("Valtech") for approximately \$340.0 million, subject to certain adjustments, with the potential for up to an additional \$350.0 million in pre-specified milestone-driven payments over the next 10 years. The transaction closed on January 23, 2017, and the consideration paid included the issuance of approximately 2.8 million shares of the Company's common stock (fair value of \$266.5 million) and cash of \$86.1 million. The Company recognized in "Other Long-term Liabilities" a \$162.9 million liability for the estimated fair value of the contingent milestone payments. The fair value of the contingent milestone payments will be remeasured each quarter, with changes in the fair value recognized within operating expenses on the consolidated statements of operations. For further information on the fair value of the contingent milestone payments, see Note 6.

In connection with the acquisition, the Company placed \$27.6 million of the purchase price into escrow to satisfy any claims for indemnification made in accordance with the merger agreement. Any funds remaining 15 months after the acquisition date will be disbursed to Valtech's former shareholders. Acquisition-related costs of \$0.6 million and \$4.1 million were recorded in "Selling, General, and Administrative Expenses" during the six months ended June 30, 2017 and the year ended December 31, 2016, respectively. Prior to the close of the transaction, Valtech spun off its early-stage transeptal mitral valve replacement technology program. Concurrent with the closing, the Company entered into an agreement for an exclusive option to acquire that program and its associated intellectual property for \$200.0 million, subject to certain adjustments, plus an additional \$50.0 million if a certain European regulatory approval is obtained within 10 years of the acquisition closing date. The option expires two years after the closing date of the transaction, but can be extended by up to one year depending on the results of certain clinical trials.

Valtech is a developer of a transcatheter mitral and tricuspid valve repair system. The Company plans to add this technology to its portfolio of mitral and tricuspid repair products. The acquisition was accounted for as a business combination. Tangible and intangible assets acquired were recorded based on their estimated fair values at the acquisition date. The excess of the purchase price over the fair value of net assets acquired was recorded to goodwill. The Company is in the process of finalizing its purchase price allocation, including the valuation of intangible assets and tax-related items. Therefore, the amounts reflected below are subject to change and will be finalized in 2017. The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed as of the acquisition date (in millions):

Current assets	\$22.7
Property and equipment, net	1.2
Goodwill	316.4
Developed technology	109.2
In-process research and development ("IPR&D")	87.9
Other assets	0.8
Current liabilities assumed	(5.1)
Deferred income taxes	(17.6)
Total purchase price	515.5
Less: cash acquired	(4.3)
Total purchase price, net of cash acquired	\$511.2

Goodwill includes expected synergies and other benefits the Company believes will result from the acquisition. Goodwill was assigned to the Company's Rest of World segment and is not deductible for tax purposes. IPR&D has been capitalized at fair value as an intangible asset with an indefinite life and will be assessed for impairment in subsequent periods. The fair value of the IPR&D was determined using the income approach. This approach determines fair value based on cash flow projections which are discounted to present value using a risk-adjusted rate of return. The discount rates used to determine the fair value of the IPR&D ranged from 18.0% to 20.0%. Completion

of successful design developments, bench testing, pre-clinical studies and human clinical studies are required prior to selling any product. The risks and uncertainties associated with completing development within a reasonable period of time include those related to the design, development, and manufacturability of the product, the success of pre-clinical and clinical studies, and the timing of regulatory approvals. The valuation assumed \$87.3 million of additional research and development expenditures would be incurred prior to the date of product introduction. In the valuation, net cash inflows were modeled to commence in 2019. Upon completion of development, the underlying IPR&D asset will be amortized over its estimated useful life. Developed technology assets are being amortized over a weighted-average useful life of 11 years.

Table of Contents

The results of operations for Valtech have been included in the accompanying consolidated financial statements from the date of acquisition. Pro forma results have not been presented as the results of Valtech are not material in relation to the consolidated financial statements of the Company.

5. INVESTMENTS

Debt Securities

Investments in debt securities at the end of each period were as follows (in millions):

	June 30, 2017				December 31, 2016			
	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value	Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Held-to-maturity								
Bank time deposits	\$505.3	\$ —	\$ —	\$505.3	\$217.0	\$ —	\$ —	\$217.0
Commercial paper	0.4	—	—	0.4	—	—	—	—
U.S. government and agency securities	5.2	—	(0.1)	5.1	16.1	—	(0.1)	16.0
Asset-backed securities	—	—	—	—	0.3	—	—	0.3
Corporate debt securities	0.9	—	—	0.9	3.0	—	—	3.0
Municipal securities	—	—	—	—	1.9	—	—	1.9
Total	\$511.8	\$ —	\$ (0.1)	\$511.7	\$238.3	\$ —	\$ (0.1)	\$238.2
Available-for-sale								
Bank time deposits	\$2.5	\$ —	\$ —	\$2.5	\$—	\$ —	\$ —	\$—
Commercial paper	35.8	—	—	35.8	35.4	—	—	35.4
U.S. government and agency securities	87.4	—	(0.5)	86.9	143.4	—	(0.7)	142.7
Foreign government bonds	11.8	0.1	—	11.9	—	—	—	—
Asset-backed securities	104.4	0.1	(0.2)	104.3	86.0	—	(0.2)	85.8
Corporate debt securities	400.6	0.8	(0.7)	400.7	333.6	0.4	(1.5)	332.5
Municipal securities	4.5	—	—	4.5	4.6	—	(0.1)	4.5
Total	\$647.0	\$ 1.0	\$ (1.4)	\$646.6	\$603.0	\$ 0.4	\$ (2.5)	\$600.9

The cost and fair value of investments in debt securities, by contractual maturity, as of June 30, 2017 were as follows:

	Held-to-Maturity		Available-for-Sale	
	Cost	Fair Value	Cost	Fair Value
	(in millions)			
Due in 1 year or less	\$506.6	\$506.5	\$ 117.1	\$ 117.0
Due after 1 year through 5 years	—	—	425.5	425.2
Instruments not due at a single maturity date	5.2	5.2	104.4	104.4
	\$511.8	\$511.7	\$ 647.0	\$ 646.6

Actual maturities may differ from the contractual maturities due to call or prepayment rights.

Table of Contents

Investments in Unconsolidated Affiliates

The Company has a number of equity investments in privately and publicly held companies. Investments in these unconsolidated affiliates are recorded in "Long-term Investments" on the consolidated condensed balance sheets, and are as follows:

	June 30,	December 31,
	2017	2016
	(in millions)	
Available-for-sale investments		
Cost	\$—	\$ —
Unrealized gains	0.1	0.1
Fair value of available-for-sale investments	0.1	0.1
Equity method investments		
Cost	9.2	9.5
Equity in losses	(4.8)	(3.9)
Carrying value of equity method investments	4.4	5.6
Cost method investments		
Carrying value of cost method investments	12.2	28.2
Total investments in unconsolidated affiliates	\$16.7	\$ 33.9

During the three and six months ended June 30, 2017, the gross realized gains or losses from sales of available-for-sale investments were not material. See Note 3 for information regarding the Company's impairment of one of its cost method investments.

6. FAIR VALUE MEASUREMENTS

The consolidated condensed financial statements include financial instruments for which the fair market value of such instruments may differ from amounts reflected on a historical cost basis. Financial instruments of the Company consist of cash deposits, accounts and other receivables, investments, accounts payable, certain accrued liabilities, and borrowings under a revolving credit agreement. These financial instruments are held at cost, which generally approximates fair value due to their short-term nature.

Financial instruments also include long-term notes payable. As of June 30, 2017, the fair value of the notes payable, based on Level 2 inputs, was \$607.2 million, versus a carrying value of \$598.4 million.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Company prioritizes the inputs used to determine fair values in one of the following three categories:

Level 1—Quoted market prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than quoted prices in active markets, that are observable, either directly or indirectly.

Level 3—Unobservable inputs that are not corroborated by market data.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Table of Contents

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table summarizes the Company's financial instruments which are measured at fair value on a recurring basis (in millions):

June 30, 2017	Level 1	Level 2	Level 3	Total
Assets				
Cash equivalents	\$53.2	\$26.6	\$—	\$79.8
Available-for-sale investments:				
Bank time deposits	—	2.5	—	2.5
Corporate debt securities	—	400.7	—	400.7
Asset-backed securities	—	104.3	—	104.3
U.S. government and agency securities	51.0	35.9	—	86.9
Foreign government bonds	—	11.9	—	11.9
Commercial paper	—	35.8	—	35.8
Municipal securities	—	4.5	—	4.5
Equity investments in unconsolidated affiliates	0.1	—	—	0.1
Investments held for deferred compensation plans	55.3	—	—	55.3
Derivatives	—	9.7	—	9.7
	\$159.6	\$631.9	\$—	\$791.5
Liabilities				
Derivatives	\$—	\$15.4	\$—	\$15.4
Deferred compensation plans	55.9	—	—	55.9
Contingent consideration liabilities	—	—	198.7	198.7
	\$55.9	\$15.4	\$198.7	\$270.0
December 31, 2016				
Assets				
Cash equivalents	\$44.1	\$—	\$—	\$44.1
Available-for-sale investments:				
Corporate debt securities	—	332.5	—	332.5
Asset-backed securities	—	85.8	—	85.8
U.S. government and agency securities	100.7	42.0	—	142.7
Commercial paper	—	35.4	—	35.4
Municipal securities	—	4.5	—	4.5
Equity investments in unconsolidated affiliates	0.1	—	—	0.1
Investments held for deferred compensation plans	46.0	—	—	46.0
Derivatives	—	35.2	—	35.2
	\$190.9	\$535.4	\$—	\$726.3
Liabilities				
Derivatives	\$—	\$3.3	\$—	\$3.3
Deferred compensation plans	46.7	—	—	46.7
Contingent consideration liabilities	—	—	31.6	31.6
	\$46.7	\$3.3	\$31.6	\$81.6

The following table summarizes the changes in fair value of the contingent consideration liabilities for the six months ended June 30, 2017 (in millions):

Balance at December 31, 2016	\$31.6
Additions	162.9

Changes in fair value	4.2
Balance at June 30, 2017	\$198.7

Table of Contents

Cash Equivalents and Available-for-sale Investments

The Company estimates the fair values of its money market funds based on quoted prices in active markets for identical assets. The Company estimates the fair values of its time deposits, commercial paper, U.S. and foreign government and agency securities, municipal securities, asset-backed securities, and corporate debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades and broker-dealer quotes on the same or similar securities, benchmark yields, credit spreads, prepayment and default projections based on historical data, and other observable inputs. The Company independently reviews and validates the pricing received from the third-party pricing service by comparing the prices to prices reported by a secondary pricing source. The Company's validation procedures have not resulted in an adjustment to the pricing received from the pricing service.

Investments in unconsolidated affiliates are long-term equity investments in companies that are in various stages of development. Certain of the Company's investments in unconsolidated affiliates are designated as available-for-sale. These investments are carried at fair market value based on quoted market prices.

Deferred Compensation Plans

The Company holds investments in trading securities related to its deferred compensation plans. The investments are in a variety of stock and bond mutual funds. The fair values of these investments and the corresponding liabilities are based on quoted market prices.

Derivative Instruments

The Company uses derivative financial instruments in the form of foreign currency forward exchange contracts to manage foreign currency exposures, and interest rate swap agreements to manage its interest rate exposures. All derivatives contracts are recognized on the balance sheet at their fair value. The fair value of foreign currency derivative financial instruments was estimated based on quoted market foreign exchange rates and market discount rates. The fair value of the interest rate swap agreements was determined based on a discounted cash flow analysis reflecting the contractual terms of the agreements and the 6-month LIBOR forward interest rate curve. Judgment was employed in interpreting market data to develop estimates of fair value; accordingly, the estimates presented herein are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The use of different market assumptions or valuation methodologies could have a material effect on the estimated fair value amounts.

Contingent Consideration Liabilities

Certain of the Company's acquisitions involve contingent consideration arrangements. Payment of additional consideration is contingent upon the acquired company reaching certain performance milestones, such as attaining specified revenue levels, achieving product development targets, or obtaining regulatory approvals. These contingent consideration liabilities are measured at estimated fair value using either a probability weighted discounted cash flow analysis or a Monte Carlo simulation model, both of which consider significant unobservable inputs. These inputs include (1) the discount rate used to present value the projected cash flows (ranging from 1.0% to 3.0%), (2) the probability of milestone achievement (ranging from 43.0% to 85.0%), (3) the projected payment dates (ranging from 2018 to 2024), and (4) the volatility of future revenue (50.0%). The use of different assumptions could have a material effect on the estimated fair value amounts.

7. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company uses derivative financial instruments to manage its currency exchange rate risk and its interest rate risk, as summarized below. It is the Company's policy not to enter into derivative financial instruments for speculative purposes. Notional amounts are stated in United States dollar equivalents at spot exchange rates at the respective dates.

	Notional Amount	
	June 30, 2017	December 31, 2016
	(in millions)	
Foreign currency forward exchange contracts	\$ 1,037.7	\$ 949.7
Interest rate swap agreements	300.0	300.0

Table of Contents

The Company uses interest rate swaps to convert a portion of its fixed-rate debt into variable-rate debt. These interest rate swaps are designated as fair value hedges and meet the shortcut method requirements under the accounting standards for derivatives and hedging. Accordingly, changes in the fair values of the interest rate swaps are considered to exactly offset changes in the fair value of the underlying long-term debt. The Company uses foreign currency forward exchange contracts to offset the changes due to currency rate movements in the amount of future cash flows associated with intercompany transactions and certain local currency expenses expected to occur within the next 13 months. These foreign currency forward exchange contracts are designated as cash flow hedges. Certain of the Company's locations have assets and liabilities denominated in currencies other than their functional currencies resulting principally from intercompany and local currency transactions. The Company uses foreign currency forward exchange contracts that are not designated as hedging instruments to offset the transaction gains and losses associated with certain of these assets and liabilities. The Company also uses foreign currency forward exchange contracts and foreign currency denominated debt to offset changes in the value of its net investment in certain foreign subsidiaries resulting from changes in foreign currency exchange rates. The foreign currency forward exchange contracts and the foreign currency denominated debt are designated as net investment hedges. All foreign currency forward exchange contracts are denominated in currencies of major industrial countries, principally the Euro and the Japanese yen.

All derivative financial instruments are recognized at fair value in the consolidated condensed balance sheets. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. The gain or loss on the interest rate swaps (designated as fair value hedges) is classified in net interest expense, as they hedge the interest rate risk associated with the Company's fixed-rate debt. The Company reports in "Accumulated Other Comprehensive Loss" the effective portion of the gain or loss on derivative financial instruments that are designated, and that qualify, as cash flow hedges. The Company reclassifies these gains and losses into earnings in the same period in which the underlying hedged transactions affect earnings. The effective portions of net investment hedges are reported in "Accumulated Other Comprehensive Loss" as a part of the cumulative translation adjustment, and would be reclassified into earnings if the underlying net investment is sold or substantially liquidated. The ineffective portions of cash flow hedges and net investment hedges are recorded in current period earnings. For the six months ended June 30, 2017 and 2016, the Company did not record any gains or losses due to hedge ineffectiveness. The gains and losses on derivative financial instruments for which the Company does not elect hedge accounting treatment are recognized in the consolidated condensed statements of operations in each period based upon the change in the fair value of the derivative financial instrument. Cash flows from net investment hedges are reported as investing activities in the consolidated condensed statements of cash flows, and cash flows from all other derivative financial instruments are reported as operating activities.

Derivative financial instruments involve credit risk in the event the counterparty should default. It is the Company's policy to execute such instruments with global financial institutions that the Company believes to be creditworthy. The Company diversifies its derivative financial instruments among counterparties to minimize exposure to any one of these entities. The Company also uses International Swap Dealers Association master-netting agreements. The master-netting agreements provide for the net settlement of all contracts through a single payment in a single currency in the event of default, as defined by the agreements.

The following table presents the location and fair value amounts of derivative instruments reported in the consolidated condensed balance sheets (in millions):

	Balance Sheet Location	Fair Value	
		June 30, 2017	December 31, 2016
Assets			
Foreign currency contracts	Other current assets	\$9.1	\$ 28.6

Edgar Filing: Edwards Lifesciences Corp - Form 10-Q

Interest rate swap agreements	Other assets	\$0.6	\$ 0.4
Liabilities			
Foreign currency contracts	Accrued and other liabilities	\$15.4	\$ 3.3
Derivatives not designated as hedging instruments			
Assets			
Foreign currency contracts	Other current assets	\$—	\$ 6.2

12

Table of Contents

The following table presents the effect of master-netting agreements and rights of offset on the consolidated condensed balance sheets (in millions):

June 30, 2017	Gross Amounts	Gross Amounts Offset in the Consolidated Balance Sheet	Net Amounts Presented in the Consolidated Balance Sheet	Gross Amounts Not Offset in the Consolidated Balance Sheet		
				Financial Instruments	Cash Collateral Received	Net Amount
Derivative assets						
Foreign currency contracts	\$ 9.1	\$	—\$ 9.1	\$ (7.3)	\$	—\$ 1.8
Interest rate swap agreements	\$ 0.6	\$	—\$ 0.6	\$ —	\$	—\$ 0.6
Derivative liabilities						
Foreign currency contracts	\$ 15.4	\$	—\$ 15.4	\$ (7.3)	\$	—\$ 8.1
December 31, 2016						
Derivative assets						
Foreign currency contracts	\$ 34.8	\$	—\$ 34.8	\$ (3.3)	\$	—\$ 31.5
Interest rate swap agreements	\$ 0.4	\$	—\$ 0.4	\$ —	\$	—\$ 0.4
Derivative liabilities						
Foreign currency contracts	\$ 3.3	\$	—\$ 3.3	\$ (3.3)	\$	—\$ —

The following tables present the effect of derivative and non-derivative hedging instruments on the consolidated condensed statements of operations and consolidated condensed statements of comprehensive income (in millions):

	Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion) Three Months Ended June 30, 2017		Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income Three Months Ended June 30, 2017	
	2017	2016		2017	2016
Cash flow hedges					
Foreign currency contracts	\$(17.6)	\$0.5	Cost of sales Selling, general, and administrative expenses	\$2.2	\$3.2
				\$0.1	\$(0.3)
Net investment hedges					
Foreign currency contracts	\$—	\$8.5			
Foreign currency denominated debt	\$(15.6)	\$—			
	Amount of Gain or (Loss) Recognized in OCI on Derivative			Amount of Gain or (Loss) Reclassified from	

Edgar Filing: Edwards Lifesciences Corp - Form 10-Q

	(Effective Portion)		Accumulated OCI into Income Six Months Ended June 30, 2017	2016
	Six Months Ended June 30, 2017	2016	Location of Gain or (Loss) Reclassified from Accumulated OCI into Income	2017
Cash flow hedges				
Foreign currency contracts	\$ (26.1)	\$ (20.5)	Cost of sales Selling, general, and administrative expenses	\$ 4.7 \$ 14.6 \$ 0.2 \$ (0.3)
Net investment hedges				
Foreign currency contracts	\$ —	\$ (3.8)		
Foreign currency denominated debt	\$ (15.6)	\$ —		

As of June 30, 2017, the Company had €370.0 million of outstanding long-term debt designated as a net investment hedge.

Table of Contents

		Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended June 30,	
Fair value hedges	Location of Gain or (Loss) Recognized in Income on Derivative	2017 2016	
Interest rate swap agreements	Interest expense, net	\$0.1 \$(0.1)	
		Amount of Gain or (Loss) Recognized in Income on Derivative Six Months Ended June 30,	
Fair value hedges	Location of Gain or (Loss) Recognized in Income on Derivative	2017 2016	
Interest rate swap agreements	Interest expense, net	\$0.2 \$4.8	
The gains on the interest rate swap agreements are fully offset by the changes in the fair value of the fixed-rate debt being hedged.			
		Amount of Gain or (Loss) Recognized in Income on Derivative Three Months Ended June 30,	
Derivatives not designated as hedging instruments	Location of Gain or (Loss) Recognized in Income on Derivative	2017 2016	
Foreign currency contracts	Other expenses, net	\$(1.1) \$(9.4)	
		Amount of Gain or (Loss) Recognized in Income on Derivative Six Months Ended June 30,	
Derivatives not designated as hedging instruments	Location of Gain or (Loss) Recognized in Income on Derivative	2017 2016	
Foreign currency contracts	Other expenses, net	\$(6.6) \$(15.8)	

The Company expects that during the next twelve months it will reclassify to earnings a \$3.2 million gain currently recorded in "Accumulated Other Comprehensive Loss."

8. STOCK-BASED COMPENSATION

Stock-based compensation expense related to awards issued under the Company's incentive compensation plans for the three and six months ended June 30, 2017 and 2016 was as follows (in millions):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2017	2016	2017	2016
Cost of sales	\$2.3	\$2.1	\$4.6	\$4.1
Selling, general, and administrative expenses	10.0	9.4	20.2	19.1
Research and development expenses	3.0	2.8	5.7	5.4
Total stock-based compensation expense	\$15.3	\$14.3	\$30.5	\$28.6

At June 30, 2017, the total remaining compensation cost related to nonvested stock options, restricted stock units, market-based restricted stock units, performance-based restricted stock units, and employee stock purchase plan ("ESPP") subscription awards amounted to \$125.7 million, which will be amortized on a straight-line basis over the weighted-average remaining requisite service period of 33 months.

Table of Contents

During the six months ended June 30, 2017, the Company granted 1.0 million stock options at a weighted-average exercise price of \$109.89 and 0.2 million shares of restricted stock units at a weighted-average grant-date fair value of \$108.28. The Company also granted 0.1 million shares of market-based and performance-based restricted stock units at a weighted-average grant-date fair value of \$129.46. In addition, the Company issued an additional 0.1 million shares related to a previous year's grant of market-based restricted stock units since the payout percentage achieved at the end of the performance period was in excess of the targeted shares. The market-based restricted stock units vest based on a combination of certain service and market conditions. The actual number of shares issued will be determined based on the Company's total shareholder return relative to a selected industry peer group over a three-year performance period, and may range from 0% to 175% of the targeted number of shares granted. The performance-based restricted stock units vest based on the achievement of specified milestones.

Fair Value Disclosures

The fair value of the market-based restricted stock units was determined using a Monte Carlo simulation model, which uses multiple input variables to determine the probability of satisfying the market condition requirements. The weighted-average assumptions used to determine the fair value of the market-based restricted stock units granted during the six months ended June 30, 2017 and 2016 included a risk-free interest rate of 1.7% and 1.0%, respectively, and an expected volatility rate of 30.2% and 30.0%, respectively.

The following table includes the weighted-average grant-date fair values of stock options granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model:

Option Awards	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2017	2016	2017	2016
Average risk-free interest rate	1.8 %	1.2 %	1.8 %	1.2 %
Expected dividend yield	None	None	None	None
Expected volatility	33.0 %	33.1 %	33.0 %	33.1 %
Expected term (years)	4.5	4.5	4.5	4.5
Fair value, per option	\$33.64	\$31.08	\$33.54	\$30.99

The following table includes the weighted-average grant-date fair values for ESPP subscriptions granted during the periods indicated and the related weighted-average assumptions used in the Black-Scholes option pricing model:

ESPP	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2017	2016	2017	2016
Average risk-free interest rate	0.5 %	0.3 %	0.4 %	0.3 %
Expected dividend yield	None	None	None	None
Expected volatility	32.8 %	32.8 %	32.9 %	29.0 %
Expected term (years)	0.6	0.6	0.6	0.6
Fair value, per share	\$29.89	\$24.92	\$25.19	\$20.85

9. COMMITMENTS AND CONTINGENCIES

On October 30, 2015, Boston Scientific Scimed, Inc., a subsidiary of Boston Scientific Corporation ("Boston Scientific"), filed a lawsuit in the district court in Düsseldorf, Germany against Edwards Lifesciences and its German subsidiary, Edwards Lifesciences Services GmbH, alleging that Edwards Lifesciences' SAPIEN 3 heart valve infringes certain claims of a Boston Scientific German national patent arising from EP 2 749 254 B1 (the "'254 patent") related to paravalvular sealing technology. On February 26, 2016, Boston Scientific added the German

national patent arising from EP 2 926 766 (the "'766 patent") to the infringement allegations. On April 8, 2016, Boston Scientific filed a similar patent infringement action in district court in Paris, France relating to these patents. The complaints seek unspecified money damages and injunctive relief. The Company intends to defend itself vigorously in these matters. The French suit has been stayed pending the outcome of validity proceedings on the '766 and '254 patents. On March 9, 2017, the German district court ruled that the SAPIEN 3 heart valve infringes the '254 and '766 patents, and that Boston Scientific is entitled to enforce an injunction against SAPIEN 3 sales in Germany upon payment of a €90.0 million bond for each patent, but has not yet elected to do so. Edwards Lifesciences has

Table of Contents

appealed this infringement decision. In addition, Edwards Lifesciences has filed oppositions at the European Patent Office ("EPO") challenging the validity of the '254 and '766 patents.

On November 2, 2015, Edwards Lifesciences LLC, a U.S. subsidiary of Edwards Lifesciences, filed a lawsuit against Sadra Medical, Inc. and Boston Scientific Scimed, Inc., two subsidiaries of Boston Scientific, in the United Kingdom in the High Court of Justice, Chancery Division, Patents Court to declare invalid and revoke the U.K. national patent corresponding to the '254 patent. Edwards Lifesciences later added Boston Scientific's U.K. national patent corresponding to the '766 patent to this invalidity lawsuit. The Boston Scientific subsidiaries filed counterclaims against Edwards Lifesciences and three of its European subsidiaries alleging that the SAPIEN 3 heart valve infringes certain claims of the same patents and seeking unspecified monetary damages and injunctive relief. On March 3, 2017, the U.K. Patents Court ruled that Boston Scientific's '254 patent is invalid, and that its '766 patent is valid and infringed. The court also ruled that Boston Scientific is entitled to an injunction against SAPIEN 3 sales in the United Kingdom, but stayed the injunction pending appeal. Both sides have appealed this decision and U.K. Patents Court Proceedings for damages are ongoing.

On June 16, 2017, Edwards Lifesciences filed a lawsuit against Boston Scientific Scimed, Inc. in Germany in the district court in Munich, seeking a court order that Edwards Lifesciences is a co-owner of the '254 patent based on rights it has acquired. Proceedings are ongoing.

On November 23, 2015, Edwards Lifesciences PVT, Inc., a U.S. subsidiary of Edwards Lifesciences, filed a lawsuit in the district court in Düsseldorf, Germany for patent infringement against Boston Scientific and a German subsidiary, Boston Scientific Medizintechnik GmbH, alleging that the Lotus heart valve infringes certain claims of Edwards Lifesciences' German national patents EP 1 441 672 B1 (the "'672 patent") and 2 255 753 B1 (the "'753 patent") related to prosthetic valve and delivery system technology. Edwards Lifesciences later added its German national patent EP 2 399 550 (the "'550 patent") to this suit. The complaint sought unspecified monetary damages and injunctive relief. On March 9, 2016, the German district court ruled that the Lotus heart valve infringes the '550 patent, but does not infringe the '672 patent. The court also ruled that Edwards Lifesciences is entitled to enforce an injunction against the sales of the Lotus valve in Germany upon the payment of a €10.0 million bond, but has not yet elected to do so. Both sides have appealed this decision. The court did not rule on the '753 patent due to an opposition filed at the EPO by Boston Scientific. On March 28, 2017, the EPO rendered an initial decision to revoke the '753 patent. Edwards Lifesciences intends to appeal the EPO's initial decision.

On April 19, 2016, Boston Scientific filed a lawsuit against Edwards Lifesciences in the Federal District Court in the District of Delaware alleging that the SAPIEN 3 heart valve infringes certain claims of Boston Scientific's U.S. Patent 8,992,608 (the "'608 patent") related to paravalvular sealing technology and seeking unspecified monetary damages and injunctive relief. On June 9, 2016, Edwards Lifesciences LLC and Edwards Lifesciences PVT, Inc. filed counterclaims alleging that Boston Scientific's Lotus heart valve infringes Edwards Lifesciences' U.S. Patents 9,168,133; 9,339,383; and 7,510,575 related to prosthetic valve technology. Trial is scheduled for July 2018. On October 12, 2016, Edwards Lifesciences filed an Inter Partes Review ("IPR") request with the U.S. Patent and Trademark Office (the "USPTO") challenging the validity of Boston Scientific's '608 patent. On March 29, 2017, the USPTO decided to institute the IPR.

Also on April 19, 2016, Boston Scientific filed a lawsuit against Edwards Lifesciences in the Federal District Court in the Central District of California alleging that five of its transcatheter heart valve delivery systems and a valve crimper infringe certain claims of eight Boston Scientific U.S. patents. The complaints seek unspecified monetary damages and injunctive relief. Trial is scheduled for May 2018. The Company intends to defend itself vigorously in these matters and has filed IPRs challenging the validity of the Boston Scientific patents in the suit. On April 21, 2017, the USPTO declined to institute one requested IPR related to a crimper patent. On June 29, 2017, the USPTO instituted a separate requested IPR related to the same crimper patent. Other IPR requests are pending.

On October 23, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences (Canada) Inc., a Canadian subsidiary of Edwards Lifesciences, filed a lawsuit against Boston Scientific and its Canadian subsidiary, Boston Scientific Ltd., as well as LivaNova PLC and LivaNova Canada Corp., its contract manufacturers, in the Federal Court in Toronto, Canada, alleging that Boston Scientific's manufacture of the Lotus valve through its contract manufacturers infringes two of Edwards Lifesciences' patents covering transcatheter heart valve technology. On February 17, 2017, Edwards added Neovasc, Inc. and Neovasc Medical Inc., additional contract manufacturers of Boston Scientific, to this lawsuit. On January 11, 2017, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA(AG), a Swiss subsidiary of Edwards Lifesciences, filed a lawsuit against Boston Scientific Ltd and Boston Scientific Group PLC, two Irish subsidiaries of Boston Scientific, in the High Court in Dublin, Ireland alleging that the Boston Scientific's manufacture of the Lotus and Lotus Edge valves infringes the '550 patent.

Table of Contents

Because the ultimate outcome of the above matters involve judgments, estimates, and inherent uncertainties, and cannot be predicted with certainty, charges related to such matters could have a material adverse impact on Edwards Lifesciences' financial position, results of operations, and liquidity.

In addition, Edwards Lifesciences is or may be a party to, or may otherwise be responsible for, pending or threatened lawsuits related primarily to products and services currently or formerly manufactured or performed, as applicable, by Edwards Lifesciences (the "Other Lawsuits"). The Other Lawsuits raise difficult and complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. Management does not believe that any charge relating to the Other Lawsuits would have a material adverse effect on Edwards Lifesciences' overall financial position, results of operations, or liquidity. However, the resolution of one or more of the Other Lawsuits in any reporting period, could have a material adverse impact on Edwards Lifesciences' net income or cash flows for that period. The Company is not able to estimate the amount or range of any loss for legal contingencies for which there is no reserve or additional loss for matters already reserved.

Edwards Lifesciences is subject to various environmental laws and regulations both within and outside of the United States. The operations of Edwards Lifesciences, like those of other medical device companies, involve the use of substances regulated under environmental laws, primarily in manufacturing and sterilization processes. While it is difficult to quantify the potential impact of continuing compliance with environmental protection laws, management believes that such compliance will not have a material impact on Edwards Lifesciences' financial position, results of operations, or liquidity.

10. ACCUMULATED OTHER COMPREHENSIVE LOSS

The following table is a summary of activity for each component of "Accumulated Other Comprehensive Loss" for the six months ended June 30, 2017 (in millions):

	Foreign Currency Translation Adjustments	Unrealized Gain (Loss) on Cash Flow Hedges	Unrealized Gain (Loss) on Available-for-sale Investments	Unrealized Pension Costs	Total Accumulated Other Comprehensive Loss
December 31, 2016	\$ (197.6)	\$ 16.7	\$ 0.1	\$ (17.6)	\$ (198.4)
Other comprehensive gain (loss) before reclassifications	55.0	(26.1)	(3.0)	0.1	26.0
Amounts reclassified from accumulated other comprehensive loss	—	(4.9)	0.8	—	(4.1)
Deferred income tax benefit	5.9	12.4	0.4	—	18.7
June 30, 2017	\$ (136.7)	\$ (1.9)	\$ (1.7)	\$ (17.5)	\$ (157.8)

The following table provides information about amounts reclassified from "Accumulated Other Comprehensive Loss" (in millions):

Details about Accumulated Other Comprehensive Loss Components	Three Months Ended		Six Months Ended		Affected Line on Consolidated Condensed Statements of Operations
	June 30, 2017	June 30, 2016	June 30, 2017	June 30, 2016	
Gain (loss) on cash flow hedges	\$2.3 (0.8)	\$2.9 (1.3)	\$4.9 (1.8)	\$14.3 (5.7)	Cost of sales Provision for income taxes
	\$1.5	\$1.6	\$3.1	\$8.6	Net of tax
Gain (loss) on available-for-sale investments	\$(0.3)	\$(0.3)	\$(0.8)	\$(0.6)	Other expenses, net Provision for income taxes
	—	—	—	—	

\$(0.3) \$(0.3) \$(0.8) \$(0.6) Net of tax

11. EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during a period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of

17

Table of Contents

dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.

The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):

	Three Months Ended June 30, 2017		Six Months Ended June 30, 2016	
Basic:				
Net income	\$186.1	\$126.6	\$416.3	\$269.6
Weighted-average shares outstanding	210.5	212.2	210.8	212.6
Basic earnings per share	\$0.88	\$0.60	\$1.97	\$1.27
Diluted:				
Net income	\$186.1	\$126.6	\$416.3	\$269.6
Weighted-average shares outstanding	210.5	212.2	210.8	212.6
Dilutive effect of stock plans	5.2	5.1	5.3	5.0
Dilutive weighted-average shares outstanding	215.7	217.3	216.1	217.6
Diluted earnings per share	\$0.86	\$0.58	\$1.93	\$1.24

Stock options, restricted stock units, and market-based restricted stock units to purchase 2.2 million and 1.1 million shares for the three months ended June 30, 2017 and 2016, respectively, and 1.7 million and 0.7 million shares for the six months ended June 30, 2017 and 2016, respectively, were outstanding, but were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive.

12. INCOME TAXES

The Company's effective income tax rates were 9.5% and 25.1% for the three months ended June 30, 2017 and 2016, respectively, and 16.6% and 23.5% for the six months ended June 30, 2017 and 2016, respectively. The change in the effective rates is primarily a result of the benefit determined under the new accounting standard for employee share-based compensation (see Note 1), and fluctuations in the relative contribution of foreign operations and United States operations to worldwide pre-tax income. The adoption of the new accounting standard for the tax benefit of employee share-based compensation resulted in a decrease in the Company's effective rates of 14.2% and 7.9% for the three and six months ended June 30, 2017, respectively.

The Company strives to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While the Company has accrued for matters it believes are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, the Company may later decide to challenge any assessments, if made, and may exercise its right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law.

At June 30, 2017, all material state, local, and foreign income tax matters have been concluded for years through 2008. The Internal Revenue Service ("IRS") has substantially completed its fieldwork for the 2009 through 2013 tax years. However, the audits are currently in suspense pending a final determination with respect to a pending

application for an Advanced Pricing Agreement ("APA") discussed below. The IRS began its examination of the 2014 tax year during the fourth quarter of 2016.

As of June 30, 2017 and December 31, 2016, the liability for income taxes associated with uncertain tax positions was \$147.1 million and \$245.5 million, respectively. The Company estimates that these liabilities would be reduced by \$19.4 million and \$44.9 million, respectively, from offsetting tax benefits associated with the correlative effects of potential transfer pricing adjustments, state income taxes, and timing adjustments. The net amounts of \$127.7 million and \$200.6 million, respectively, if not required, would favorably affect the Company's effective tax rate. The significant decrease in the net amount during the year is a result of the Company's anticipated partial settlement of the APA discussed below.

The Company has been pursuing an APA between the Switzerland and United States governments for the years 2009 through 2013 covering transfer pricing matters with the possibility of a roll-forward of the results to subsequent years. During

18

Table of Contents

the first quarter of 2017, an agreement was reached on several of the transactions covered by the APA. As a result, the Company anticipates that it will make payments related to these transactions within the next twelve months. Therefore, a reclassification was made during the first quarter from the long-term liability for uncertain tax positions to current taxes payable for the portion that relates to these transactions. Negotiations on other significant transaction flows remain ongoing as of June 30, 2017. Overall, transfer pricing matters continue to be significant to the Company's consolidated financial statements as the disputed amounts are material, and the final outcome is uncertain. The Company continues to believe its positions are supportable.

During 2014, the Company filed with the IRS a request for a pre-filing agreement associated with a tax return filing position on a portion of the litigation settlement payment received in May 2014. During the first quarter of 2015, the IRS accepted the Company's request into the pre-filing agreement program. The closing agreement for this matter was finalized during the fourth quarter of 2016. There remains a disputed issue and the Company was accepted into the Fast-Track Appeals process in July 2017. The Company made an advance payment of tax in December 2015 to prevent the further accrual of interest on any potential deficiency, and not to signify any potential agreement to a contrary position that may be taken by the IRS.

13. SEGMENT INFORMATION

Edwards Lifesciences conducts operations worldwide and is managed in the following geographical regions: United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease.

The Company's geographic segments are reported based on the financial information provided to the Chief Operating Decision Maker (the Chief Executive Officer). The Company evaluates the performance of its geographic segments based on net sales and income before provision for income taxes ("pre-tax income"). The accounting policies of the segments are substantially the same as those described in Note 2 of the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2016. Segment net sales and segment pre-tax income are based on internally derived standard foreign exchange rates, which may differ from year to year, and do not include inter-segment profits. Because of the interdependence of the reportable segments, the operating profit as presented may not be representative of the geographical distribution that would occur if the segments were not interdependent. Net sales by geographic area are based on the location of the customer.

Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include net interest expense, global marketing expenses, corporate research and development expenses, manufacturing variances, corporate headquarters costs, special gains and charges, stock-based compensation, foreign currency hedging activities, certain litigation costs, and most of the Company's amortization expense. Although most of the Company's depreciation expense is included in segment pre-tax income, due to the Company's methodology for cost build-up, it is impractical to determine the amount of depreciation expense included in each segment, and, therefore, a portion is maintained at the corporate level. The Company neither discretely allocates assets to its operating segments, nor evaluates the operating segments using discrete asset information.

The table below presents information about Edwards Lifesciences' reportable segments (in millions):

	Three Months Ended		Six Months Ended	
	June 30, 2017	June 30, 2016	June 30, 2017	June 30, 2016
Segment Net Sales				
United States	\$478.9	\$401.5	\$943.5	\$777.1
Europe	181.2	198.0	446.5	385.1

Edgar Filing: Edwards Lifesciences Corp - Form 10-Q

Japan	91.3	71.9	173.1	135.7
Rest of World	92.5	77.0	174.3	148.5
Total segment net sales	\$843.9	\$748.4	\$1,737.4	\$1,446.4
Segment Pre-tax Income				
United States	\$314.7	\$260.2	\$618.2	\$501.8
Europe	79.5	98.2	231.6	192.9
Japan	52.8	38.6	98.8	68.1
Rest of World	27.3	19.1	52.7	37.0
Total segment pre-tax income	\$474.3	\$416.1	\$1,001.3	\$799.8

19

Table of Contents

The table below presents reconciliations of segment net sales to consolidated net sales and segment pre-tax income to consolidated pre-tax income (in millions):

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2017	2016	2017	2016
Net Sales Reconciliation				
Segment net sales	\$843.9	\$748.4	\$1,737.4	\$1,446.4
Foreign currency	(2.1)	10.9	(12.1)	10.2
Consolidated net sales	\$841.8	\$759.3	\$1,725.3	\$1,456.6
Pre-tax Income Reconciliation				
Segment pre-tax income	\$474.3	\$416.1	\$1,001.3	\$799.8
Unallocated amounts:				
Corporate items	(223.7)	(206.3)	(443.3)	(401.5)
Special charges (Note 3)	(31.2)	(34.5)	(31.2)	(34.5)
Intellectual property litigation expenses	(7.7)	(9.1)	(17.9)	(21.3)
Interest expense, net	(1.4)	(2.4)	(3.8)	(4.8)
Foreign currency	(4.7)	5.2	(5.9)	14.6
Consolidated pre-tax income	\$205.6	\$169.0	\$499.2	\$352.3

Enterprise-wide Information

Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated condensed financial statements.

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2017	2016	2017	2016
(in millions)				
Net Sales by Geographic Area				
United States	\$478.9	\$401.5	\$943.5	\$777.1
Europe	183.7	203.6	444.7	392.1
Japan	90.5	79.9	169.8	146.5
Rest of World	88.7	74.3	167.3	140.9
	\$841.8	\$759.3	\$1,725.3	\$1,456.6
Net Sales by Major Product and Service Area				
Transcatheter Heart Valve Therapy	\$487.5	\$418.6	\$1,026.7	\$786.4
Surgical Heart Valve Therapy	207.1	198.7	406.6	394.6
Critical Care	147.2	142.0	292.0	275.6
	\$841.8	\$759.3	\$1,725.3	\$1,456.6

	June	December
	30,	31, 2016
	2017	
(in millions)		
Long-lived Tangible Assets by Geographic Area		
United States	\$589.7	\$555.5
Europe	30.4	27.9
Japan	7.7	8.0

Rest of World	113.2	108.6
	\$741.0	\$ 700.0

20

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend the forward-looking statements contained in this report to be covered by the safe harbor provisions of such Acts. All statements other than statements of historical fact in this report or referred to or incorporated by reference into this report are "forward-looking statements" for purposes of these sections. These statements include, among other things, any predictions of earnings, revenues, expenses or other financial items, plans or expectations with respect to development activities, clinical trials or regulatory approvals, any statements of plans, strategies and objectives of management for future operations, any statements concerning our future operations, financial conditions and prospects, and any statements of assumptions underlying any of the foregoing. These statements can sometimes be identified by the use of the forward-looking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "pro forma," "forecast," "intend," "guidance," "optimistic," "aspire," "confident," other forms of these words or similar words or expressions or the negative thereof. Investors are cautioned not to unduly rely on such forward-looking statements. These forward-looking statements are subject to substantial risks and uncertainties that could cause our results or future business, financial condition, results of operations or performance to differ materially from our historical results or experiences or those expressed or implied in any forward-looking statements contained in this report. Investors should carefully review the information contained in, or incorporated by reference into, our annual report on Form 10-K for the year ended December 31, 2016 and subsequent reports on Forms 10-Q and 8-K for a description of certain of these risks and uncertainties. These forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If we do update or correct one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.

Overview

We are the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Driven by a passion to help patients, we partner with the world's leading clinicians and researchers and aggressively invest in

research and development to transform care for structural heart disease and critically ill patients. We conduct operations

worldwide and are managed in the following geographical regions: United States, Europe, Japan, and Rest of World.

Our products are categorized into the following main areas: Transcatheter Heart Valve Therapy ("THVT"), Surgical Heart Valve

Therapy ("SHVT"), and Critical Care.

Financial Highlights

Our sales growth was led by our THVT products, primarily increased sales of the Edwards SAPIEN 3 transcatheter heart valve in the United States, Japan, and Europe. In the first quarter of 2017, customers in Germany elected to purchase additional inventory of SAPIEN 3 in anticipation of a potential supply interruption resulting from recent intellectual property litigation in

Table of Contents

that country. In the second quarter, customers consumed part, but not all, of this inventory. Our gross profit in 2017 was positively impacted by an improved product mix, led by THVT products. The increase in our net income was primarily driven by our increased sales and favorable income tax rate, partially offset by an impairment charge in the second quarter of 2017 related to certain long-term assets.

Healthcare Environment, Opportunities, and Challenges

The medical technology industry is highly competitive and continues to evolve. Our success is measured both by the development of innovative products and the value we bring to our stakeholders. We are committed to developing new technologies and providing innovative patient care, and we are committed to defending our intellectual property in support of those developments. In the first six months of 2017, we invested 15.2% of our net sales in research and development.

New Accounting Standards

For information on new accounting standards, see Note 1 to the "Consolidated Condensed Financial Statements."

Results of Operations**Net Sales Trends**

(dollars in millions)

	Three Months Ended			Percent Change	Six Months Ended			Percent Change
	June 30, 2017	2016	Change		June 30, 2017	2016	Change	
United States	\$478.9	\$401.5	\$ 77.4	19.3 %	\$943.5	\$777.1	\$ 166.4	21.4 %
International	362.9	357.8	5.1	1.5 %	781.8	679.5	102.3	15.1 %
Total net sales	\$841.8	\$759.3	\$ 82.5	10.9 %	\$1,725.3	\$1,456.6	\$ 268.7	18.4 %

International net sales include the impact of foreign currency exchange rate fluctuations. The impact of foreign currency exchange rate fluctuations on net sales is not necessarily indicative of the impact on net income due to the corresponding effect of foreign currency exchange rate fluctuations on international manufacturing and operating costs, and our hedging activities. For more information, see Item 3, "Quantitative and Qualitative Disclosures About Market Risk."

Net Sales by Product Group

(dollars in millions)

	Three Months Ended			Percent Change	Six Months Ended			Percent Change
	June 30, 2017	2016	Change		June 30, 2017	2016	Change	
Transcatheter Heart Valve Therapy	\$487.5	\$418.6	\$ 68.9	16.5 %	\$1,026.7	\$786.4	\$ 240.3	30.6 %
Surgical Heart Valve Therapy	207.1	198.7	8.4	4.2 %	406.6	394.6	12.0	3.0 %
Critical Care	147.2	142.0	5.2	3.7 %	292.0	275.6	16.4	6.0 %
Total net sales	\$841.8	\$759.3	\$ 82.5	10.9 %	\$1,725.3	\$1,456.6	\$ 268.7	18.4 %

Table of Contents

Transcatheter Heart Valve Therapy

The increase in net sales of THVT products in the United States was due primarily to:

• the Edwards SAPIEN 3 valve, driven by strong therapy adoption;

The increase in international net sales of THVT products was due to:

• the Edwards SAPIEN 3 valve, primarily increased sales in (1) Japan, driven by its launch in March 2016, and (2) Europe, for the year-to-date period, notably in Germany as customers elected to purchase additional inventory during the first quarter of 2017 in anticipation of a potential supply interruption resulting from recent intellectual property litigation in that country. In the second quarter, customers consumed part, but not all, of this inventory;

partially offset by:

• lower sales of the Edwards SAPIEN XT valve in Japan as customers converted to Edwards SAPIEN 3.

In June 2017, we received United States Food and Drug Administration ("FDA") approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve for patients at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve.

Table of Contents

Surgical Heart Valve Therapy

The increase in net sales of SHVT was driven by:

• mitral tissue valves, primarily in the United States and Rest of World, due to the recovery from the supply interruption we experienced in mid-2016; and

• the EDWARDS INTUITY Elite Valve System, primarily in the United States;

partially offset by:

• surgical aortic tissue valves, primarily in the United States, as customers converted to transcatheter aortic valves.

In July 2017, we received FDA approval for our INSPIRIS RESILIA aortic valve, the first in a new class of resilient heart valves.

Table of Contents

Critical Care

The increase in net sales of Critical Care products was driven by enhanced surgical recovery products in the United States and Rest of World, and core hemodynamic products, primarily in Rest of World.

In April 2017, we received FDA clearance for our HemoSphere advanced monitoring platform. This technology provides clinicians with clarity on a patient's hemodynamics, or the factors that manage blood flow, to help them make proactive, timely clinical decisions.

Gross Profit

The increase in gross profit as a percentage of net sales for the three and six months ended June 30, 2017 was driven primarily by a 1.4 percentage point and 1.5 percentage point increase, respectively, in the United States due to an improved product mix, driven by THVT products.

Table of Contents

Selling, General, and Administrative ("SG&A") Expenses

The increase in SG&A expenses for the three and six months ended June 30, 2017 was due primarily to higher sales and marketing expenses in the United States and Europe, mainly to support the THVT program. The decrease in SG&A expenses as a percentage of net sales for the three and six months ended June 30, 2017 was due primarily to higher THVT sales in the United States and Japan.

Research and Development ("R&D") Expenses

The increase in R&D expenses for the three and six months ended June 30, 2017 was due primarily to mitral, aortic, and tricuspid THVT product development efforts, including development expenses associated with the Cardioband Reconstruction System, and several small purchases during the first quarter of 2017 of transcatheter mitral valve repair technologies.

Table of Contents

Special Charges

In June 2017, we recorded a \$31.2 million charge related to the other-than-temporary impairment of one of our cost method investments and an associated long-term asset related to our option to acquire this investee. We concluded that the impairment of these assets was other-than-temporary based upon recent review of the investee's clinical data and trial results, which did not support continuation of the product development effort, and the financial condition and near term prospects of the investee.

In May 2016, we entered into two separate agreements to acquire technologies for use in our THVT programs. In connection with these agreements, we recorded an IPR&D charge totaling \$34.5 million. The acquired technologies are in the early stages of development and have no alternative uses. Additional design developments, bench testing, pre-clinical studies, and human clinical studies must be successfully completed prior to selling any product using these technologies.

Other Expenses, net
(in millions)

	Three Months Ended June 30, 2017		Six Months Ended June 30, 2016	
Foreign exchange losses, net	\$2.7	\$0.8	\$4.0	\$0.4
Loss (gain) on investments	0.7	(0.7)	1.6	(1.4)
Charitable foundation contribution	—	—	—	5.0
Other	0.1	—	0.2	0.1
Other expenses, net	\$3.5	\$0.1	\$5.8	\$4.1

The net foreign exchange losses relate primarily to the foreign currency fluctuations in our global trade and intercompany receivable and payable balances, offset by the gains and losses on derivative instruments intended as an economic hedge of those exposures.

The loss (gain) on investments primarily represents our net share of gains and losses in investments accounted for under the equity method, and realized gains and losses on our available-for-sale and cost method investments.

In March 2016, we contributed \$5.0 million to the Edwards Lifesciences Foundation, a related-party not-for-profit organization intended to provide philanthropic support to health- and community-focused charitable organizations. The

contribution was irrevocable and was recorded as an expense at the time of payment.

Provision for Income Taxes

The provision for income taxes consists of provisions for federal, state, and foreign income taxes. We operate in an international environment with significant operations in various locations outside the United States, which have statutory tax rates lower than the United States tax rate. Accordingly, the consolidated income tax rate is a composite rate reflecting the earnings in the various locations and the applicable rates.

Our effective income tax rate was 9.5% and 25.1% for the three months ended June 30, 2017 and 2016, respectively, and 16.6% and 23.5% for the six months ended June 30, 2017 and 2016, respectively. The change in the effective rates is primarily a result of the benefit determined under the new accounting standard for employee share-based compensation, and fluctuations in the relative contribution of foreign operations and United States operations to worldwide pre-tax income. The adoption of the new accounting standard for employee share-based compensation

resulted in a decrease in our effective tax rates of 14.2% and 7.9% for the three and six months ended June 30, 2017, respectively.

We strive to resolve open matters with each tax authority at the examination level and could reach agreement with a tax authority at any time. While we have accrued for matters we believe are more likely than not to require settlement, the final outcome with a tax authority may result in a tax liability that is more or less than that reflected in the consolidated condensed financial statements. Furthermore, we may later decide to challenge any assessments, if made, and may exercise our right to appeal. The uncertain tax positions are reviewed quarterly and adjusted as events occur that affect potential liabilities for additional taxes, such as lapsing of applicable statutes of limitations, proposed assessments by tax authorities, negotiations between tax authorities, identification of new issues, and issuance of new legislation, regulations, or case law. Management believes that adequate amounts of tax and related penalty and interest have been provided in income tax expense for any

Table of Contents

adjustments that may result from our uncertain tax positions. For further information, see Note 12 to the "Consolidated Condensed Financial Statements."

We have been pursuing an Advance Pricing Agreement ("APA") between the Switzerland and United States governments for the years 2009 through 2013 covering transfer pricing matters with the possibility of a roll-forward of the results to subsequent years. During the first quarter of 2017, an agreement was reached on several of the transactions covered by the APA. As a result, we anticipate that we will make payments related to these transactions within the next twelve months. Therefore, a reclassification was made during the first quarter from the long-term liability for uncertain tax positions to current taxes payable for the portion that relates to these transactions. Negotiations on other significant transaction flows remain ongoing as of June 30, 2017. Overall, transfer pricing matters continue to be significant to our consolidated financial statements as the disputed amounts are material, and the final outcome is uncertain. We continue to believe that our positions are supportable.

During 2014, we filed with the Internal Revenue Service ("IRS") a request for a pre-filing agreement associated with a tax return filing position on a portion of the litigation settlement payment received from Medtronic in May 2014. During the first quarter of 2015, the IRS accepted the pre-filing agreement into the pre-filing agreement program. The closing agreement for this matter was finalized during the fourth quarter of 2016. There remains a disputed issue and we were accepted into the Fast-Track Appeals process in July 2017. We made an advance payment of tax in December 2015 solely to prevent the further accrual of interest on any potential deficiency, and not to signify any potential agreement to a contrary position that may be taken by the IRS.

Liquidity and Capital Resources

Our sources of cash liquidity include cash and cash equivalents, short-term investments, amounts available under credit facilities, and cash from operations. We believe that these sources are sufficient to fund the current requirements of working capital, capital expenditures, and other financial commitments for the next twelve months. However, we periodically consider various financing alternatives and may, from time to time, seek to take advantage of favorable interest rate environments or other market conditions.

As of June 30, 2017, cash and cash equivalents and short-term investments held in the United States and outside the United States were \$129.1 million and \$1.0 billion, respectively. We believe that cash held in the United States, in addition to amounts available under credit facilities and cash from operations, are sufficient to fund our United States operating requirements for the next twelve months. Cash and cash equivalents and short-term investments held outside the United States, the majority of which relates to undistributed earnings of certain of our foreign subsidiaries, which are considered by us to be indefinitely reinvested, have historically been used to fund international operations and acquire businesses and assets outside of the United States. We consider making short-term loans of cash held outside the United States to the United States from time to time based on facts and circumstances. The permanent repatriations of cash and cash equivalents and short-term investments held outside the United States are subject to restrictions in certain jurisdictions, and may be subject to withholding and other taxes. The potential tax liability related to any repatriation would be dependent on the facts and circumstances that exist at the time such repatriation is made and the complexities of the tax laws of the United States and the respective foreign jurisdictions.

On November 26, 2016, we entered into an agreement and plan of merger to acquire Valtech Cardio Ltd. ("Valtech") for approximately \$340.0 million, subject to certain adjustments, in stock and cash to be paid at closing, with the potential for up to \$350.0 million in additional pre-specified milestone-driven payments over the next 10 years. Our acquisition of Valtech closed on January 23, 2017, and we issued an aggregate of approximately 2.8 million shares of our common stock, and paid approximately \$86.1 million in cash to holders of Valtech securities. Prior to the close of the transaction, Valtech spun off its early-stage transseptal mitral valve replacement technology program. We have an option to acquire that program and its associated intellectual property for approximately \$200.0 million, subject to certain adjustments, plus an additional \$50.0 million if a certain European regulatory approval is obtained within 10 years of the acquisition closing date. For further information, see Note 4 to the "Consolidated Condensed Financial Statements."

We have a Five-Year Credit Agreement ("Credit Agreement") which provides up to an aggregate of \$750.0 million in borrowings in multiple currencies. We may increase the amount available under the Credit Agreement, subject to agreement of the lenders, by up to an additional \$250.0 million in the aggregate. As of June 30, 2017, borrowings of \$418.4 million were outstanding under the Credit Agreement, and have been classified as long-term obligations in accordance with the terms of the Credit Agreement. In October 2013, we issued \$600.0 million of 2.875% fixed-rate unsecured senior notes due October 15, 2018. As of June 30, 2017, the total carrying value of our long-term debt was \$1.0 billion.

From time to time, we repurchase shares of our common stock under share repurchase programs authorized by the Board of Directors. We consider several factors in determining when to execute share repurchases, including, among other things,

Table of Contents

expected dilution from stock plans, cash capacity, and the market price of our common stock. During 2017, we repurchased a total of 5.3 million shares at an aggregate cost of \$501.0 million, and as of June 30, 2017, had remaining authority to purchase \$530.1 million of our common stock.

At June 30, 2017, there had been no material changes in our significant contractual obligations and commercial commitments as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016.

Consolidated Cash Flows - For the six months ended June 30, 2017 and 2016:

Net cash flows provided by operating activities of \$326.0 million for the six months ended June 30, 2017 increased \$28.6 million over the same period last year due primarily to improved operating performance, partially offset by higher working capital needs associated with growth in the business and the timing of tax payments.

Net cash used in investing activities of \$487.0 million for the six months ended June 30, 2017 consisted primarily of net purchases of investments of \$322.0 million, an \$81.8 million net cash payment associated with the acquisition of Valtech, and capital expenditures of \$73.9 million.

Net cash used in investing activities of \$295.8 million for the six months ended June 30, 2016 consisted primarily of net purchases of investments of \$194.4 million and capital expenditures of \$64.8 million.

Net cash used in financing activities of \$264.5 million for the six months ended June 30, 2017 consisted primarily of purchases of treasury stock of \$511.2 million, partially offset by net proceeds from debt of \$177.2 million and proceeds from stock plans of \$68.7 million.

Net cash used in financing activities of \$337.4 million for the six months ended June 30, 2016 consisted primarily of purchases of treasury stock of \$415.7 million, including amounts paid under accelerated repurchase agreements, partially offset by proceeds from stock plans of \$44.6 million.

Critical Accounting Policies and Estimates

The consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated condensed financial statements and revenues and expenses during the periods reported. Actual results could differ from those estimates. Information with respect to our critical accounting policies and estimates which we believe could have the most significant effect on our reported results and require subjective or complex judgments by management is contained on pages 39-42 in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations," of our Annual Report on Form 10-K for the year ended December 31, 2016. There have been no significant changes from the information discussed therein.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk, Foreign Currency Risk, Credit Risk, and Concentrations of Risk

For a complete discussion of our exposure to interest rate risk, foreign currency risk, credit risk, and concentrations of risk, refer to Item 7A "Quantitative and Qualitative Disclosures About Market Risk" on pages 42-43 of our Annual Report on Form 10-K for the year ended December 31, 2016. There have been no significant changes from the information discussed therein.

Table of Contents

Investment Risk

We are exposed to investment risks related to changes in the underlying financial condition and credit capacity of certain of our investments. As of June 30, 2017, we had \$1.2 billion of investments in fixed-rate debt securities of various companies, of which \$534.8 million were long-term. In addition, we had \$16.7 million of investments in equity instruments of public and private companies. Should these companies experience a decline in financial condition or credit capacity, or fail to meet certain development milestones, a decline in the investments' value may occur, resulting in unrealized or realized losses.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures. Our management, including the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of June 30, 2017. Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded as of June 30, 2017 that our disclosure controls and procedures are effective in providing reasonable assurance that the information we are required to disclose in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in our internal controls over financial reporting during the quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II. Other Information

Item 1. Legal Proceedings

Please see Note 9 to the "Consolidated Condensed Financial Statements" of this Quarterly Report on Form 10-Q, which is incorporated by reference.

Item 1A. Risk Factors

There have been no material changes to the risk factors under Part I, Item 1A "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

Period	Total Number of Shares (or Units) Purchased (a)	Average Price Paid per Share (or Unit)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs (in millions) (b)
April 1, 2017 through April 30, 2017	693,486	\$ 93.87	692,398	\$ 530.1
May 1, 2017 through May 31, 2017	78,701	110.58	—	530.1
June 1, 2017 through June 30, 2017	—	—	—	530.1
Total	772,187	95.57	692,398	

The difference between the total number of shares (or units) purchased and the total number of shares (or units) (a) purchased as part of publicly announced plans or programs is due to shares withheld by us to satisfy tax withholding obligations in connection with the vesting of restricted stock units issued to employees.

On November 10, 2016, the Board of Directors approved a stock repurchase program authorizing us to purchase on (b) the open market, including pursuant to a Rule 10b5-1 plan and in privately negotiated transactions, up to \$1.0 billion of our common stock.

Item 5. Other Information

At the Edwards Lifesciences' Annual Meeting of Stockholders in May 2017, stockholders approved a non-binding advisory proposal to vote on the Company's named executive officer compensation every year. The Company will include a non-binding advisory stockholder vote on the compensation of its named executive officers in its proxy materials every year until the next advisory vote on the frequency of stockholder votes on its named executive officer

compensation.

Item 6. Exhibits

The exhibits listed in the Exhibit Index (following the signature page of this report) are filed, furnished, or incorporated by reference as part of this report on Form 10-Q.

31

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

EDWARDS LIFESCIENCES
CORPORATION
(Registrant)

Date: July 28, 2017 By: /s/ SCOTT B. ULLEM

Scott B. Ullem
Chief Financial Officer
(Principal Financial Officer)

Date: July 28, 2017 By: /s/ ROBERT W.A. SELLERS

Robert W.A. Sellers
Corporate Controller
(Principal Accounting Officer)

Table of Contents

EXHIBITS FILED WITH SECURITIES AND EXCHANGE COMMISSION

Exhibit No.	Description
	Amendment No. 1, dated May 5, 2017, to the Five-Year Credit Agreement among Edwards Lifesciences Corporation and certain of its subsidiaries, as Borrowers; the lenders signatory thereto, Bank of America, N.A., as Administrative Agent, Swing Line Lender and Issuing Bank; JPMorgan Chase Bank, N.A.
10.1	and Wells Fargo Bank, National Association, as Co-Syndication Agents; and Deutsche Bank Securities Inc., HSBC Bank USA, National Association, PNC Bank, National Association, The Bank of Tokyo-Mitsubishi UFJ, Ltd., and U.S. Bank National Association, as Co-Documentation Agents Amendment No. 1 to the Edwards Lifesciences
10.2	Corporation Severance Pay Plan, dated April 26, 2017
31.1	Certification Pursuant to

- Section 302 of the
Sarbanes-Oxley
Act of 2002
Certification
Pursuant to
- 31.2 Section 302 of the
Sarbanes-Oxley
Act of 2002
Certification
Pursuant to 18
U.S.C.
- 32 Section 1350, as
Adopted Pursuant
to Section 906 of
the Sarbanes-Oxley
Act of 2002
The following
financial statements
from Edwards
Lifesciences'
Quarterly Report
on Form 10-Q for
the quarter ended
June 30, 2017,
formatted in XBRL
(eXtensible
Business Reporting
Language): (i) the
Consolidated
Condensed Balance
Sheets, (ii) the
Consolidated
- 101 Condensed
Statements of
Operations, (iii) the
Consolidated
Condensed
Statements of
Comprehensive
Income, (iv) the
Consolidated
Condensed
Statements of Cash
Flows, and
(v) Notes to
Consolidated
Condensed
Financial
Statements